Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention
| Autor: | Kwon Sam Kim, Myeong Kon Kim, Jong Shin Woo, Sang Jin Ha, Seok-Jae Hwang, Soo-Joong Kim, Weon Kim, Woo-Shik Kim |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Blood Platelets
medicine.medical_specialty Ticlopidine Time Factors Randomization Platelet Function Tests medicine.medical_treatment Drug Resistance Tetrazoles Coronary Artery Disease Coronary Angiography Percutaneous Coronary Intervention P2Y12 Internal medicine Republic of Korea medicine Humans Platelet Prospective Studies cardiovascular diseases Cross-Over Studies business.industry Percutaneous coronary intervention General Medicine Clopidogrel Cilostazol Treatment Outcome Diabetes Mellitus Type 2 Pharmacodynamics Adjunctive treatment Cardiology Drug Therapy Combination Cardiology and Cardiovascular Medicine business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Coronary Artery Disease. 24:690-697 |
| ISSN: | 0954-6928 |
| DOI: | 10.1097/mca.0000000000000026 |
| Popis: | BACKGROUND We investigated the pharmacodynamic effect of cilostazol addition (100 mg twice, Triple) or clopidogrel doubling (150 mg daily, Double) on standard dual antiplatelet therapy in type 2 diabetes mellitus (T2DM) patients with clopidogrel resistance undergoing a percutaneous coronary intervention. METHODS AND RESULTS This was a prospective, randomized, cross-over platelet function study. Percent inhibition less than 20% was used as the cutoff value of clopidogrel resistance. After percutaneous coronary intervention, a total of 50 T2DM patients with clopidogrel resistance were assigned to receive cilostazol 100 mg twice daily or clopidogrel 150 mg daily for 28 days; afterwards, they received cross-over treatment for another 28 days. Eight patients were excluded because of side effects and follow-up loss. The platelet function test using VerifyNow was performed at three time points: at baseline (T0), 28 days after randomization (T1), and 28 days after cross-over treatment (T2).A total of 42 T2DM patients completed the study protocol. The clopidogrel resistance improved significantly following cilostazol addition or clopidogrel doubling treatment compared with baseline (52.9±27.0 in Triple, 45.4±16.8% in Double, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|